ams-OSRAM (OTCMKTS:AMSSY) Shares Gap Down – Time to Sell?

ams-OSRAM AG Unsponsored ADR (OTCMKTS:AMSSY) gapped down before the market opened on Tuesday . The stock had previously closed at $5.03, but opened at $4.51. ams-OSRAM shares last traded at $4.51, with a volume of 200 shares.

Analysts Set New Price Targets

Several brokerages recently issued reports on AMSSY. Jefferies Financial Group downgraded shares of ams-OSRAM from a “strong-buy” rating to a “hold” rating in a research note on Friday, November 21st. Barclays reaffirmed a “cautious” rating on shares of ams-OSRAM in a research report on Tuesday, September 16th. One equities research analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, ams-OSRAM presently has a consensus rating of “Reduce”.

ams-OSRAM Stock Performance

The firm has a fifty day moving average of $5.96 and a 200 day moving average of $6.26. The firm has a market capitalization of $900.60 million, a PE ratio of -5.01 and a beta of 0.97. The company has a debt-to-equity ratio of 2.50, a quick ratio of 0.62 and a current ratio of 1.23.

ams-OSRAM (OTCMKTS:AMSSY) last issued its quarterly earnings data on Tuesday, November 18th. The company reported $0.16 earnings per share (EPS) for the quarter. ams-OSRAM had a negative net margin of 4.86% and a positive return on equity of 2.61%. The company had revenue of $997.09 million during the quarter, compared to the consensus estimate of $963.90 million. Equities research analysts expect that ams-OSRAM AG Unsponsored ADR will post 0.67 EPS for the current year.

ams-OSRAM Company Profile

ams-OSRAM AG designs, manufactures, and sells LED and optical sensor solutions in Europe, the Middle East, Africa, the Americas, and Asia/Pacific. The company operates in Semiconductors and Lamps & Systems segments. The Semiconductors segment offers semiconductor-based products and solutions, such as high-performance LEDs, lasers, and optical sensors for automotive, consumer, and industrial and medical technology end markets.